Mangoceuticals (MGRX) Accumulated Expenses (2022 - 2026)

Mangoceuticals (MGRX) posted Accumulated Expenses of $3297.0 for Q1 2026, down 65.0% sequentially from $9421.0 in Q4 2025.

Mangoceuticals (MGRX) Accumulated Expenses (2022 - 2026) Analysis & Trends

Mangoceuticals has reported Accumulated Expenses for 5 years, with the latest figure at $3297.0 in Q1 2026.

Quarterly Accumulated Expenses changed N/A year-over-year to $3297.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3297.0 (changed N/A YoY) and the FY2025 annual result came in at $9421.0, changed N/A from the prior year.
Accumulated Expenses fell to $3297.0 in Q1 2026 per MGRX's latest filing, from $9421.0 in the prior quarter.
Over five years, Accumulated Expenses peaked at $9421.0 in Q4 2025 and troughed at $2717.0 in Q4 2022.
A 5-year average of $5556.8 and a median of $5133.5 in 2024 frame the typical range for Accumulated Expenses.
The sharpest annual moves came in 2023 and 2025: Accumulated Expenses jumped 142.73% in 2023, then sank 36.57% in 2025.
Over 5 years, Accumulated Expenses stood at $2717.0 in 2022, then surged by 142.73% to $6595.0 in 2023, then retreated by 15.39% to $5580.0 in 2024, then surged by 68.84% to $9421.0 in 2025, then slumped by 65.0% to $3297.0 in 2026.
According to Business Quant data, Accumulated Expenses over the past three periods registered $3297.0, $9421.0, and $4460.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Veeva Systems	39.72 Bn	32.40 Bn	662.02 Mn
2	BrightSpring Health Services	12.19 Bn	11.64 Bn	492.75 Mn
3	Healthequity	8.79 Bn	8.52 Bn	256.31 Mn
4	10x Genomics	7.31 Bn	6.76 Bn	112.50 Mn
5	Hinge Health	7.10 Bn	6.71 Bn	183.95 Mn
6	MiniMed	5.66 Bn	5.36 Bn	480.00 Mn
7	Waystar Holding	4.76 Bn	4.56 Bn	221.99 Mn
8	Doximity	4.46 Bn	3.77 Bn	132.93 Mn
9	Heartflow	3.66 Bn	3.28 Bn	53.19 Mn
10	Mangoceuticals	9.55 Mn	9.30 Mn	44,215.00

Download Data